Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 551–600 of 711 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07022223	Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma	recruiting	Phase 2	51	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Jun 15, 2025	clinicaltrials
NCT05253495	Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma(RADICAL)	recruiting	Phase 2	80	New York Medical CollegeOTHER	1	Jun 13, 2025